We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fecal Calprotectin Predicts Complete Mucosal Healing in UC

By LabMedica International staff writers
Posted on 13 Nov 2017
Print article
Image: The rapid Quantum Blue Fecal Calprotectin lateral flow test (Photo courtesy of Bühlmann Laboratories).
Image: The rapid Quantum Blue Fecal Calprotectin lateral flow test (Photo courtesy of Bühlmann Laboratories).
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by a disease course involving relapses and remissions. Historically, clinical remission was the major treatment target for patients with UC.

The use of repeated endoscopy to verify mucosal healing (MH) is invasive, inconvenient, and expensive, and may present a risk of significant complications such as colonic perforation. Therefore, noninvasive surrogate markers indicating endoscopic healing have been investigated to replace the repeated endoscopic procedures.

Scientists at the University of Ulsan College of Medicine (Seoul, Republic of Korea) collected 181 fecal samples from 181 consecutive UC patients between April 2015 and September 2016. Collected data included birth date, sex, date of UC diagnosis, family history of IBD, smoking status, maximum disease extent, and medications. The laboratory test results, partial Mayo Score (pMS), and colonoscopic imaging findings at Fecal Calprotectin (FC) level measurement were retrospectively reviewed.

FC levels were measured using the Quantum Blue Calprotectin rapid test (Bühlmann Laboratories AG, Schönenbuch, Switzerland), and high-range kit measuring 100–1,800 mg/kg was used. The following laboratory parameters were recorded at the time of FC level measurement: complete blood cell count on the XE-2100 (Sysmex Corporation, Kobe, Japan), including white blood cell count, hemoglobin level, hematocrit value, and platelet count; erythrocyte sedimentation rate (ESR); and serum chemistry values on the Cobas 8000 modular analyzer (Roche Diagnostics, Basel, Switzerland), and the AU5800 (Beckman Coulter, Brea, CA, USA), including C-reactive protein (CRP) and albumin levels.

The investigators found that among the biochemical markers, FC levels exhibited significant correlations with the CRP and serum albumin. The other laboratory values including white blood cell count, hematocrit values, platelet and ESR exhibited weaker correlations with the FC levels, as compared to both the CRP and serum albumin levels. The FC cut-off level of 187.0 mg/kg indicated complete mucosal healing with a sensitivity and specificity of 0.857 and 0.891, respectively.

The authors concluded that the FC level is significantly correlated with the clinical disease activity index, endoscopic indices, and serum inflammatory biomarkers in a Korean UC cohort. FC is highly predictive of complete mucosal healing in UC. UC endoscopic index of severity (UCEIS) exhibits a stronger correlation with the FC level; as compared to the Mayo endoscopic subscore (MES). Thus, FC could be used as a reliable noninvasive indicator for evaluating disease activity and mucosal healing in UC. The study was published on October 23, 2017, in the journal BMC Gastroenterology.

New
Gold Member
RPR and TPLA Assays
SEKURE RPR and TPLA Assays
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Drug Detection Platform
ABSOLUDY Drug Detection Platform
New
Preterm Delivery Test
PREMAQUICK

Print article

Channels

Molecular Diagnostics

view channel
Image: New Alzheimer’s studies have revealed disease biology, risk for progression, and potential for a novel blood test (Photo courtesy of Adobe Stock)

Novel Blood Test Could Reveal Alzheimer’s Disease Biology and Risk for Progression

The inability to diagnose Alzheimer’s disease, the most prevalent form of dementia in the elderly, at an early stage of molecular pathology is considered a key reason why treatments fail in clinical trials.... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The Accelerate WAVE system delivers rapid AST directly from positive blood culture bottles (Photo courtesy of Accelerate Diagnostics)

Rapid Diagnostic System to Deliver Same-Shift Antibiotic Susceptibility Test Results

The World Health Organization estimates that sepsis impacts around 49 million people worldwide each year, resulting in roughly 11 million deaths, with about 1.32 million of these deaths directly linked... Read more

Pathology

view channel
Image: Virtual birefringence imaging and histological staining of amyloid deposits in label-free tissue (Photo courtesy of Ozcan Research Group)

AI-Based Tissue Staining Detects Amyloid Deposits Without Chemical Stains or Polarization Microscopy

Systemic amyloidosis, a disorder characterized by the buildup of misfolded proteins in organs and tissues, presents significant diagnostic difficulties. The condition affects millions of people each year,... Read more

Industry

view channel
Image: The Scopio X100 and X100HT full-field digital cell morphology solution (Photo courtesy of Beckman Coulter)

Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership

Since 2022, Beckman Coulter (Brea, CA, USA) and Scopio Labs (Tel Aviv, Israel) have been working together to accelerate adoption of the next generation of digital cell morphology. Scopio's X100 and X100HT... Read more
CELLAVISION AB